Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo

Recent financial data reveals a significant shift in the pharmaceutical landscape as the drug Skyrizi has officially surpassed Humira in global sales, marking a pivotal transition for the manufacturer AbbVie. This change is driven by a strategy known as product hopping, where companies encourage patients to move from older medications facing generic competition to newer, patented treatments. While affordable biosimilar alternatives to Humira have finally gained some market share, their impact is being neutralized because the overall demand for adalimumab is shrinking. Consequently, the success of these newer therapies poses a challenge to market competition, as the potential for lower-cost alternatives is undermined by a rapid migration toward next-generation biological products.